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Abstract. Autonomic dysfunction is very common in patients with dementia, and its presence might also help in differential
diagnosis among dementia subtypes. Various central nervous system structures affected in Alzheimer’s disease are also implicated
in autonomic nervous system regulation, and it has been hypothesized that the deficit in central cholinergic function observed
in Alzheimer’s disease could likely lead to autonomic dysfunction. Several feasible tests can be used in clinical practice for the
assessment of parasympathetic and sympathetic functions, especially in terms of cardiovascular autonomic modulation. In this
review, we describe the different tests available and the evidence from the literature which indicate a definite presence of autonomic
dysfunction in dementia at various degrees. Importantly, the recognition of dysautonomia, besides possibly being an early
marker of dementia, would help prevent the disabling complications which increase the risk of morbidity, institutionalization,
and mortality in these individuals.
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Alzheimer’s disease (AD) is a progressive neurode-21
generative disorder and the leading cause of dementia22
worldwide. AD affects more than 20% of individuals23
over 80 years of age, and its prevalence is expected24
to rise with the increase of life expectancy. How-25
ever, there is still a limited understanding of this26
disease and its underlying causes, and existing drugs27
only provide symptomatic benefits but there are no
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currently available disease-modifying therapies [1]. It 28
is now established that the two major protein abnor- 29
malities in AD brain pathology are amyloid- (A) 30
deposition and tau accumulation. Besides these, other 31
mechanism might contribute to sporadic AD, such 32
as those suggested by the vascular hypothesis, which 33
states that cardiovascular diseases are an important 34
causal or contributing factor in AD, with hyperten- 35
sion regarded as the most powerful vascular risk factor 36
for AD (Fig. 1) [2, 3]. Indeed, cardiovascular fac- 37
tors are commonly recognized as risk factors for AD, 38
however, the relationship between cardiovascular fac- 39
tors and AD-related neurodegeneration is not clearly 40
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Fig. 1. Hypothetical model of multifactorial Alzheimer’s disease (AD) pathogenesis. AD is likely to be caused by interactions among mul-
tiple factors, including amyloid- protein precursor (APP)/amyloid- (A), tau, apolipoprotein E (ApoE4), and vascular abnormalities. A
accumulation in brain results from increased A production from APP, decreased degradation, or reduced clearance across the dysfunctional
blood-brain barrier. A accumulation leads to the formation of A oligomers and amyloid plaques, which are toxic to neurons, whereas its
accumulation in the perivascular region leads to cerebral amyloid angiopathy, which disrupts vessel function. Vascular injury also induces
toxic accumulation and capillary hypoperfusion, leading to early neuronal dysfunction. A aggregation amplifies neuronal dysfunction, impairs
synaptic functions, triggers the release of neurotoxic mediators from microglial cells, and contributes to disease propagation. The lipid transport
protein ApoE is primarily synthesized by astrocytes and microglia and once lipidated forms lipoprotein particles. Lipidated ApoE binds soluble
A and promotes A uptake through cell-surface receptors or thorough the blood-brain barrier. The ApoE4 isoform impairs A clearance and
promotes A deposition. Both A and hypoperfusion can induce tau hyperphosphorylation, leading to neurofibrillary tangle formation.
understood [3]. A system that could be implicated41
in this relationship between vascular disease and AD42
is the cholinergic system. The cholinergic system is43
a crucial regulator of the cardiovascular and auto-44
nomic functions, and it is prominently affected in AD,45
beginning in the pre-clinical phases. Various lines of46
evidence indicate that in AD the cortical perivascular47
cholinergic nerve terminals are largely lost, contribut-48
ing to the impairment of the observed reduction in49
cerebral blood flow: the analysis of this relationship has50
also led to the cholinergic-vascular hypothesis [4, 5].51
Moreover, various central nervous system structures52
affected in AD are also implicated in autonomic ner- 53
vous system regulation, such as hypothalamus, locus 54
coeruleus, cerebral neocortex, insular cortex, and brain 55
stem [6]. Thus, a deficit in central cholinergic function 56
could likely lead to autonomic dysfunction, suggest- 57
ing that a link between higher cerebral and autonomic 58
neural functions could be reasonably hypothesized in 59
dementia. To date, however, the autonomic involve- 60
ment in AD has received only limited attention even 61
though its investigation could have important clinical 62
potential, because the recognition of autonomic fail- 63
ure in AD might prevent the disabling complications 64
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Table 1
Autonomic function tests
Test System explored Advantages Disadvantages
Heart Rate Interval Variability Cardiac sympathovagal balance Simple, non-invasive Unknown
Ewing’s battery tests Cardiac sympathovagal balance Simple, non-invasive Require some degree of collaboration
from the subject
Baroreflex Baroreflex function Simple, non-invasive Unknown
Carotid Sinus Massage Carotid sinus reflex sensitivity Simple, non-invasive Should be avoided in patients with
ventricular arrythmia events, recent
myocardial infarction or
cerebro-vascular events
Plasma epinephrine and
norepinephrine measurement
Adrenergic system Simple, non-invasive High variability
Cardiac MIBG scintigraphy Adrenergic innervation of the heart In vivo evaluation of cardiac
innervation
Invasive, expensive, available only in
specialized centers
of postural dizziness, syncope and falls, which increase65
the risk of morbidity, institutionalization, and mortality66
in these individuals [7].67
Thus, in this review, we will focus on the principal68
tests used to evaluate sympathetic and parasympathetic69
dysfunction, and we will also report the evidence on70
autonomic dysfunction in AD from the literature.71
SYMPATHOVAGAL FUNCTION72
ASSESSMENT IN AD PATIENTS73
The sympathetic and parasympathetic nervous sys-74
tem are key regulators of important functions, as blood75
pressure (BP), heart rate (HR), respiration, gastroin-76
testinal, endocrine, urinary continence, and sexual77
function [8, 9]. Several autonomic function tests have78
been developed in order to investigate the severity79
and distribution of autonomic dysfunction, to evaluate80
the orthostatic intolerance, to diagnose the autonomic81
neuropathy, and to monitor the course of autonomic82
dysfunction and the response to eventual treatment [8].83
Furthermore, autonomic function tests are an important84
tool in research studies investigating cardiovascular85
and neurological disease pathophysiology. The central86
nervous system structures related to the sympatho-87
vagal network are hypothalamic structures such as88
paraventricular nucleus, dorsomedial nucleus, lateral89
hypothalamic area, posterior hypothalamic nucleus,90
and mammillary nucleus. These structures control both91
the sympathetic and parasympathetic outflow. The92
extra-hypothalamic structures related to sympathetic93
drive are locus coeroleus, rostral and ventrolateral cau-94
dal medulla, and raphe nuclei, with respect to other95
extra-hypothalamic structures such as dorsal motor96
nucleus of vagus, amygdala, and nucleus ambygus97
that control the parasympathetic drive [10]. Several of98
these structures like hypothalamus, locus coeroleus,99
and insular cortex are primarily involved in AD, there-100
fore it is reasonable to think that there should be a 101
connection between AD pathogenesis and sympatho- 102
vagal drive [11]. Here we describe some of the methods 103
used to assess autonomic function in AD (Table 1). 104
Heart rate interval variability 105
After the patient stays calm, in a rest supine position 106
for about 10–15 minutes, a continuous electrocardio- 107
gram (ECG) is recorded for 5 minutes and both the 108
time-domain indexes and frequency-domain indexes 109
are calculated [12]. Time-domain indexes are a statis- 110
tical calculation of consecutive R-R intervals. In this 111
case, during the continuous 5 minutes ECG record- 112
ing all QRS complexes and all normal to normal 113
(NN) intervals are detected. From this information 114
the mean HR, mean NN interval, difference between 115
longer-shorter NN can be calculated. Another statisti- 116
cal variable derived from this analysis is the standard 117
deviation of NN intervals (SDNN). Frequency-domain 118
indexes are a spectral method that analyses the fluc- 119
tuations in the frequency domain. The average of 120
R-R intervals undergoes Fourier transform algorithm 121
to obtain the power spectral density, so the units of 122
cycles/beat are converted in cycles/s (Hz). From the 123
above calculations low frequency (0.04–0.15 Hz) and 124
high frequency bands (0.15–0.4 Hz) are obtained. The 125
low frequency/high frequency bands ratio is used as 126
a marker of sympathovagal balance. This is a simple, 127
non-invasive method and taking advantage on the little 128
cooperation needed, it can be used even in the advanced 129
stage AD patient [13]. 130
Ewing’s battery tests 131
Five simple, noninvasive cardiovascular reflex tests 132
have been used by Ewing and colleagues to assess auto- 133
nomic function in diabetic patients [14]. Thereafter, 134
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their use has been widespread in the evaluation of auto-135
nomic function in several clinical settings, providing136
accuracy and reliability in the assessment of the auto-137
nomic system. The five tests used in Ewing’s standard138
battery are: the heart rate responses to the Valsalva139
maneuver, standing up (30:15 ratio), and deep breath-140
ing (maximum-minimum heart rate); the BP responses141
to standing up (postural BP change), and sustained142
handgrip.143
Valsalva ratio144
The Valsalva maneuver consists in performing145
forced expiration for 15 seconds at a pressure of146
40 mmHg. The Valsalva ratio is calculated dividing the147
maximal R-R interval during 15 seconds of expiration148
by the minimal R–R interval during the maneuver [15].149
Heart rate response to standing150
Physiologically, after standing an increase in heart151
rate occurs; this reaches its maximum at about the 15th152
beat after standing, followed by a relative bradycardia,153
maximal around the 30th beat. The ratio of maximum154
R–R interval at the 30th beat to the minimum R–R155
interval at the 15th beat represents the 30:15 ratio.156
R–R interval variation (RRIV) during rest and157
deep breathing (DB)158
This method is also performed by ECG recordings159
after about 5–10 minutes of rest in supine position160
[16]. In this position the patient is invited to per-161
form forced DB at 6 breaths/minutes (5 seconds for162
inspiration and 5 seconds for expiration), controlled163
by ECG recordings. According to the longest and164
the shortest R-R interval duration (in rest or during165
forced DB), the mean R-R is calculated. Difference166
between longest and shortest R-R interval duration is167
the average between them. The ratio between mean and168
average R–R interval is considered as the RRIV. The169
RRIV at rest is a simple method that can be performed170
in most of the patients with AD [17]. However, per-171
forming this test in advanced stage AD patients can be172
potentially difficult.173
Blood pressure variation (BP)174
Orthostatic hypotension is evaluated by monitor-175
ing BP in supine position after 10 minutes of rest176
and then after 3 minutes of active standing position.177
According to other protocols, BP monitoring is also178
performed during a) Valsalva maneuver, evaluated as179
the BP response by the difference between the peak180
systolic BP during the maneuver and the mean sys-181
tolic BP prior to the maneuver. The BP behavior during182
Valsalva maneuver is described in four phases as the 183
act of blowing induces a transient rise in BP (phase 184
I), thereafter the reduced preload manifests as reduced 185
BP (early phase II), this reduction induces a BP rise 186
as a result of baroreflex activation (late phase II); then 187
the patient stops the maneuver and the BP starts falling 188
(phase III), and in the end the vascular peripheral resis- 189
tance increases and the BP rises (phase IV); b) BP 190
control during isometric exercise (or handgrip): the 191
patient is invited to remain in a sitting position for 192
at least 3 minutes after 10–15 minutes of resting in 193
supine position. In this case the BP response is cal- 194
culated as difference between the mean diastolic BP 195
prior to sitting position and just before the end of sitting 196
exercise; in the handgrip tests, handgrip is maintained 197
at 30% of the maximum voluntary contraction using 198
a dynamometer for up to 5 minutes. The difference 199
between the diastolic BP just before release of hand- 200
grip, and before starting, is taken as the test measure; 201
c) Cold presser test: diastolic BP variation is evaluated 202
after the participant submerges his left hand in cold 203
water at 4◦C [18]. According to the Ewing’s classifi- 204
cation, the subjects cardiovascular autonomic function 205
can be normal (all tests normal or one borderline), early 206
impaired (one of the three heart rate tests abnormal or 207
two borderline), definitely impaired (two or more of 208
the heart rate tests abnormal), severely impaired (two 209
or more of the heart rate tests abnormal plus one or both 210
of the BP tests abnormal or both borderline) or atyp- 211
ical (any other combination). In the Ewing’s battery, 212
the heart rate tests better evaluate the parasympathetic 213
function, while the BP tests measure the sympathetic 214
function. 215
Baroreﬂex (BR) estimation 216
BR is the mechanism responsible for BP and HR 217
control. Sudden changes of BP activate the BR and, as 218
a result of sympathovagal activation, HR is modulated 219
in order to restore the BP. BR estimation consists of 220
ECG recordings and BP control at the same time [19]. 221
To study the eventual BR modification in AD the casual 222
ARXAR model has been used, which describes the 223
casual relationship between R–R interval and BP [20]. 224
Carotid sinus (CS) massage 225
CS reflex sensitivity is measured by the response 226
of HR and BP after 5–10 seconds of CS massage. 227
After 5 seconds, a fall in HR can be noticed and 228
after 20 seconds, a fall in BP is usually found. How- 229
ever this assessment should be avoided in patients 230
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with ventricular arrhythmia events, recent myocardial231
infarction, or cerebrovascular events [21].232
Plasma epinephrine and norepinephrine233
measurement234
The plasmatic level of cathecolamines is evaluated235
after 30 minutes in resting supine position and after 5236
minutes of orthostatic standing. Blood samples should237
be kept in ice and spun within 1 hour after collection.238
Plasma should then be stored at −80◦C [22]. Plasmatic239
levels of cathecolamines have been evaluated also dur-240
ing the cold presser test. In the same conditions also241
the cortisol and ACTH levels have been evaluated [23].242
123I-MIBG scintigraphy243
Another method to study the sympathetic drive244
in cardiovascular impairment is iodine-123 meta-245
iodobenzylguanidine (123I-MIBG) imaging. Non-246
invasive imaging with iodinated MIBG can assess247
efferent adrenergic neuronal functions in the heart, as248
the MIBG competes with noreadrenaline for neuronal249
uptake. A reduced MIBG uptake has been correlated250
to sympathetic dysfunction in heart failure and dia-251
betic neuropathy [24, 25]. Recent studies indicate that252
sympathetic overdrive, represented by reduced MIBG253
uptake without cardiac pathology involvement, may254
indicate also a central nervous system involvement255
[26, 27]. Indeed, it is now established that altered256
myocardial MIBG uptake can help in the differential257
diagnosis between Parkinson disease and secondary258
parkinsonisms, as well as to differentiate between259
dementia with Lewy body (DLB) and AD [28, 29].260
Other methods described in literature for the eval-261
uation of the autonomic function comprise: Holter262
ECG recording, autonomic urinary test performed263
by cistometric studies, gastrointestinal test as gastric264
scintigraphy, thermoregulatory sweat test, phenyle-265
phrine and pilocarpine eye drop test.266
In summary, we believe that a proper use of the auto-267
nomic function test would be not only valuable for the268
research studies in patients with dementia, but could269
also bring a benefit to the diagnosis, prognosis and to270
eventual therapy follow-up.271
CLINICAL EVIDENCE ON ALZHEIMER’S272
DISEASE AND AUTONOMIC273
DYSFUNCTION274
As stated above, autonomic dysfunction, present in275
all the common dementia subtypes, is believed to be276
caused by generalized underactivity of the choliner- 277
gic system. According to Perry et al. in dementia the 278
parasympathetic and sympathetic systems are affected 279
by a widespread deficit in cholinergic function and all 280
the common subtypes of dementia have been asso- 281
ciated with cholinergic deficits [30]. Evidence from 282
previous studies has shown alterations in autonomic 283
modulation in AD, either in terms of impaired vagal 284
parasympathetic function or as altered sympathetic 285
response to orthostasis [17, 22]. 286
Braak suggests a sequence of six stages of AD based 287
on progressive involvement of the two main brain 288
structures implicated in autonomic control, insular cor- 289
tex, and brainstem. He speculated that these structures 290
may be affected by neurodegeneration in a “preclin- 291
ical stage” and that the autonomic dysfunction may 292
be present before the onset of clinical symptoms of 293
dementia [6]. Thus, autonomic dysfunction may be 294
a novel biomarker of neurodegeneration. Also Royall 295
et al. suggest that AD is associated with both insu- 296
lar pathology and autonomic dysfunction. Their data 297
indicate that the right hemisphere metabolic changes, 298
showed in the preclinical AD pathology, are signif- 299
icantly associated with mortality in non-demented 300
elderly persons. Furthermore they have measured abso- 301
lute insular cerebral blood flow (CBF) by dynamic 302
contrast MRI. They noticed that the absolute reduc- 303
tions in right insular CBF and relatively reduced right 304
versus left insular CBF are associated with orthosta- 305
sis in the same population. These observations indicate 306
that the prevalence of preclinical AD is probably higher 307
than the number of demented cases and that the tests 308
on the right hemisphere functions may be useful in 309
detecting those at risk. Moreover, AD treatment is 310
essential for delaying the progressions of symptoms 311
and might also have an impact on related autonomic 312
dysfunction [31]. In previous reports, cardiac auto- 313
nomic dysfunction in AD patients, measured by heart 314
rate variability (HRV) assessment, showed a significant 315
correlation with blood levels of acetylcholinesterase 316
activity, suggesting that the presence of autonomic 317
cardiac dysfunction in AD patients might be due to 318
a cholinergic deficit in the peripheral autonomic ner- 319
vous system [32]. Moreover, autonomic tests have also 320
shown significant correlations with specific neuropsy- 321
chiatric deficits in AD, hypothesizing that a lack of 322
cortical modulation can play a role [33]. 323
Collins et al. examined dysautonomia in patients 324
with mild cognitive impairment (MCI). MCI rep- 325
resents the earliest clinical stage of AD and other 326
dementias and is characterized by impairment in mem- 327
ory and/or others cognitive domains but preserved 328
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functional abilities [34]. In this study, all subjects329
underwent Ewing’s battery tests to examine the auto-330
nomic function and neuropsychological assessment331
to evaluate the degree of cognitive impairment. MCI332
patients presented with significant autonomic dysfunc-333
tion compared with controls. The parasympathetic334
system was mainly involved in the autonomic dysfunc-335
tion as demonstrated by the deficits in the HR responses336
to cardiovascular reflex tests and reduced high fre-337
quency on HRV. The predominance of parasympathetic338
dysfunction in MCI suggests that neurodegeneration339
may be due to an early cholinergic deficiency that340
involves central autonomic network in dementia [18].341
As previously mentioned, cardiovascular factors are342
now commonly accepted as risk factors for AD and343
the BR alterations have been considered as a possible344
link between BP control and AD [35]. The BR is a345
reflex loop with cardiac, vascular, and cerebral com-346
ponents involved in a short term BP regulation, acting347
through the autonomic nervous system by restoring348
sudden changes in BP through the modulation of heart349
rate and vascular tone.350
Meel-van den Abeelen et al. compared BR function351
in patients with AD, MCI, and healthy elderly subjects.352
In AD, the BR was measured in basal conditions and353
after cholinesterase inhibitors treatment. They found a354
close relationship between AD and reduced BR func-355
tion, suggesting that the cholinergic system might play356
a role. Indeed, cholinesterase inhibitors increased BR357
function in AD. Moreover, MCI patients showed an358
intermediate BR function between normal and AD359
subjects [19].360
Van Beek et al. interestingly reported that ortho-361
static tolerance was preserved in AD, probably due362
to enhanced sympathetic tone, and galantamine did363
not affect orthostatic tolerance or HR in AD patients364
[36]. Moreover, a study investigating the association365
of the hypotensive syndromes orthostatic hypotension,366
postprandial hypotension, and carotid sinus hypersen-367
sitivity with cognitive impairment has shown that the368
prevalence of cognitive impairment was similar across369
the hypotensive syndromes and not significantly differ-370
ent from controls. However, all patients with dementia371
in this study had higher baseline HR, which could be372
suggestive of cholinergic function impairment [37].373
The majority of studies, using a combination of car-374
diovascular reflex tests and HRV, reported different375
modifications of the sympathetic and parasympathetic376
system in dementia. De Vilhena Toledo and Junqueira377
evaluated AD subjects with mild to severe cognitive378
dysfunction, assessed by CAMCOG, the cognitive part379
of the Cambridge Examination for Mental Disorders,380
and the Mini-Mental State Examination (MMSE). 381
These patients showed subtle, relative, and abso- 382
lute depression of parasympathetic modulation and 383
only relative sympathetic over activity [38]. Positive 384
correlations were found between indexes of cardiac 385
parasympathetic modulation of short-term HRV and 386
the cognitive performance assessed by the CAMCOG 387
and MMSE tests scores, while a trend for negative 388
correlation was reported for the sympathetic activ- 389
ity. The authors conclude that the more deficient the 390
cognitive performance, the less is the parasympathetic 391
modulation, and the higher the trend to sympathetic 392
hyperactivity. 393
Pascualy et al. examined the effects of AD on 394
hypothalamic-pituitary-adrenocortical (HPA) axis and 395
the sympathetic nervous system responses to a stan- 396
dardized aversive stressor. Subjects included AD and 397
cognitively normal elderly. The authors measured 398
plasma adrenocorticotropin hormone (ACTH), corti- 399
sol, norepinephrine, and epinephrine responses to a 400
1-min te cold pressor test. The cortisol response was 401
increased in the AD group but the ACTH response did 402
not differ between groups. Basal norepinephrine con- 403
centrations were higher in the AD group and although 404
norepinephrine responses to cold pressor test did not 405
differ between groups, the BP response was higher in 406
the AD subjects. These results suggest that in AD there 407
is an increased HPA axis responsiveness to cold pressor 408
test at the level of the adrenal cortex and an increase 409
in basal sympathoneural activity and in cardiovascu- 410
lar responsiveness to sympathoneural stimulation [23]. 411
A previous report from our group has also indicated 412
that other possible markers of sympathetic overactivity, 413
as G-protein coupled receptor kinase 2 (GRK2) pro- 414
tein levels in circulating lymphocyte, are upregulated 415
in AD patients with both mild and moderate/severe 416
clinical manifestations of the syndrome and are sig- 417
nificantly correlated with the severity of cognitive 418
impairment [39]. In cardiovascular disease, lympho- 419
cyte GRK2 protein levels are an emerging biomarker 420
of sympathetic dysfunction with important prognostic 421
implications [40] and several lines of evidence suggest 422
that GRK2 could also play a crucial role in AD-related 423
neurodegeneration [41]. 424
Recent studies have compared the prevalence of 425
autonomic dysfunction in different dementia subtypes. 426
In particular, Allan and colleagues evaluated patients 427
with AD, DLB, vascular dementia (VaD), and Parkin- 428
son’s disease dementia (PDD). The authors enrolled 429
elderly patient (>65 years) and clinical autonomic 430
function tests were carried out according to Ewing’s 431
battery [14]. The results emphasized that there were 432
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important differences between the four types of demen-433
tia, with orthostatic hypotension being prevalent in all434
patients with dementia, implying the need for further435
research in orthostatic hypotension as a modifiable risk436
factor for falls in these patients. Indeed, autonomic dys-437
function occurred in all subtypes of dementia but was438
especially noticeable in PDD and DLB with important439
implications for patient management [15].440
In a previous study, Allan and colleagues had441
also examined the prevalence and severity of auto-442
nomic symptoms in patients with different subtypes443
of dementia and their association with levels of phys-444
ical activity, activities of daily living, depression, and445
quality of life. They enrolled patients affected by PDD,446
DLB, VaD, AD, and healthy controls. They noticed,447
also in this study, that the autonomic symptoms were448
significantly higher in PDD, DLB, and VaD patients449
than either controls or AD patients. Moreover the auto-450
nomic symptom scores were associated with poorer451
outcomes in physical activity, activity of daily living,452
depression, and quality of life [42].453
Recent data point out important therapeutic impli-454
cations, showing that cholinesterase inhibitors can455
modulate autonomic function in patients with AD.456
Indeed, treatment with these drugs was associated with457
functional improvement of the autonomic nervous sys-458
tem behavior and to a decrease orthostatic BP in AD459
patients [43].460
CONCLUSIONS461
As the elderly population grows, the prevalence of462
patients with dementia will contextually increase, pos-463
ing a challenge for accurate clinical management not464
only of the cognitive aspects of these diseases, but also465
of their associate conditions, among which autonomic466
dysfunction plays an important role. Autonomic failure467
may occur as part of the dementing process, as some468
authors suggest, can be the result of altered response469
to stress conditions or might be exacerbated by drugs470
interfering with the autonomic function. Moreover, the471
existence of modifications of the cardiac sympatho-472
vagal balance toward a higher sympathetic and lower473
parasympathetic modulation are highly prevalent in474
elderly and may contribute to disrupted homeostatic475
adaptive capacity. In any case, it is likely to expect476
a higher proportion of abnormal autonomic manifes-477
tations and symptoms in patients with dementia, thus478
a thorough clinical autonomic assessment for elderly479
demented patient must be performed, taking advan-480
tage of several non-invasive tests available. However,481
further studies with standard methodologies in larger 482
groups of patients are advisable, in order to improve 483
the benefits of these tests in clinical practice. Moreover, 484
prospective studies are needed, evaluating whether the 485
early detection of autonomic dysfunction in dementia 486
might favorably impact patients clinical management. 487
In addition to that, autonomic derangement itself could 488
be an early biomarker in dementia diagnosis, and could 489
also help in the differential diagnosis among dementia 490
subtypes. 491
Importantly, the impact of autonomic dysfunction 492
on key symptoms such as dizziness, syncope, falls, 493
constipation, and incontinence needs to be carefully 494
investigated in patients with dementia. Future studies 495
should address whether multi-factorial interventions 496
can improve autonomic function in these patients, 497
improving quality of life and preventing the disabling 498
complications which increase the risk of morbidity, 499
institutionalization, and mortality in these individuals. 500
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